Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fedratinib

- PMLiVE

NICE backs Celgene’s Revlimid in bone marrow disorder

Recommends that drug can be used on NHS to treat myelodysplastic syndromes

- PMLiVE

Celgene’s Abraxane authorised by Health Canada

Drug can now be used as first-line treatment for metastatic pancreatic cancer

- PMLiVE

NICE set to block post-Velcade use of Revlimid

Watchdog's new draft guidance does not recommend Celgene blood cancer drug

- PMLiVE

Celgene’s cancer drug promising in small HIV study

Lymphoma therapy Istodax shows potential in treating the virus

Celgene leadership changes spark succession speculation

Movement at biotech includes promotions for Mark Alles and Jacqualyn Fouse

- PMLiVE

Global pancreatic cancer market to treble in value

Celgene's Abraxane will drive rapid growth over next three years

- PMLiVE

Celgene gets FDA OK for first oral psoriatic arthritis drug

Otezla wins US approval to treat the auto-immune disease

- PMLiVE

Celgene appoints UK inflammation and immunology director

Rob Moore joins from Abbott

- PMLiVE

Celgene wins EU pancreatic cancer approval for Abraxane

Adds to drug's existing breast cancer indication

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

- PMLiVE

Revlimid performance leads Celgene to trio of PMEAs

Wins Small Company of the Year thanks to work on rare cancer drug

Sanofi reception

Sanofi pulls development of blood cancer drug

Fedratinib linked to brain disorder during clinical trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links